Wegovy maker Novo Nordisk’s sales hike in second quarter
Boxes of Ozempic and Wegovy made by Novo Nordisk at a pharmacy in London on March 8, 2024.
Hollie Adams | Reuters
Novo Nordisk on Wednesday posted second-quarter sales broadly in line with expectations, after last week cutting its full-year guidance and announcing its new CEO.
Overall revenues rose 13% year-on-year at constant exchange rates to 76.86 billion Danish kroner ($11.92 billion) over the period, just ahead of the 76.6 billion Danish kroner forecast.
Quarterly net profit came in at 26.5 billion Danish kroner, versus 26.6 billion Danish kroner analysts expected.
This is a developing story. Please check back for updates.
